Why clinical development’s next AI bottleneck is not the model, but the system around it.
News|Webcasts|November 10, 2023
How to Achieve Comprehensive Oversight of Your Entire Portfolio of Clinical Trials
Author(s)IQVIA
Webinar Date/Time: Tuesday, December 12th, 2023 at 11am EST | 8am PST | 4pm GMT | 5pm CET
Join a webcast to hear what 110 colleagues of yours say about their challenges and desires around trial oversight, and learn how IQVIA is responding.
Register Free:
Event overview
If you are a small or mid-size pharma company without a simple solution to continuously consolidate multi-source CRO data into standardized views and analytics, you are left in a bind. You need current data from vendors for actionable oversight, but often only get those insights via vendors’ monthly reports. The varying data cadence of multiple vendors means you are typically working with some data that is relatively new and other data that older by a month or more—hardly a comprehensive picture of a trial to reassure executives’ oversight concerns.
IQVIA’s Clinical Data Analytics Suite (CDAS) can solve this challenge and give customers easy-to-use dashboards and a real-time view of critical KPIs regardless of who is conducting individual trials. CDAS is self-service and vendor-agnostic, meaning even with multiple vendors and formats, setting up this solution to bring your portfolio data into a current, harmonized, and easy-to-report format is quite simple and cost-effective.
Three key take-aways
- What are the challenges, levels of satisfaction, and desires of sponsors in terms of clinical trial portfolio oversight?
- What are optimal ways to improve trial portfolio oversight?
- Learn how a platform for clinical data analytics and AI/automation can benefit sponsors in their trial oversight efforts
Speakers:
Wendy Morahan
Sr. Director, Product CDAS
IQVIA Technologies
Wendy has 25+ years’ experience in the life sciences industry, with a career spanning academic research, preclinical drug discovery, and clinical trials culminating in a focus and passion for delivering technology solutions that help bring treatments to patients faster. Wendy is currently part of the product strategy leadership team for IQVIA Clinical Data Analytics Suite (CDAS), providing both SaaS solutions for the market as well as IQVIA’s internal CRO needs. As part of the CDAS team, Wendy is responsible for strategy, product management leadership, and go-to market activities.
Gary Shorter
Head, AI and Data Science
IQVIA Technologies
Gary pursues the use of emerging technology to provide new and more efficient capabilities to enhance clinical trial management. This includes development of new design software that supports recent advancements with AI capabilities. His team has developed several micro-products and micro-services that can be plugged in and used by any SaaS solution.
Register Free:
Related to this article
Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO partnerships is set to become a defining characteristic of successful biopharma companies.
Clinical trials have spent decades perfecting data capture, but the execution layer underneath it, including decision workflows, data collection design, and lab connectivity, remains fragmented in ways that limit what AI can realistically deliver and that quietly compromise the scientific validity of the data itself.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
In this Q&A, John Worden, chief commercial officer at Javara, discusses why clinical trial recruitment has remained stubbornly one-size-fits-all, how AI can identify patients at scale without displacing the clinician relationships that drive trust, and what care-integrated research engagement needs to look like for health systems, sponsors, and sites.
Participant engagement depends more on clarity and understanding than on gamification or incentives, requiring engagement embedded into trial workflows as a core design component rather than a peripheral consideration
Trending on Applied Clinical Trials Online
1
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
4
What "Patient Voice" Actually Requires: Beyond the Buzzword
5